LifeStance Health Group (NASDAQ:LFST) Releases Earnings Results, Beats Expectations By $0.03 EPS

Posted by Brenda Bartman on Aug 8th, 2026

LifeStance Health Group (NASDAQ:LFST – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03, FiscalAI reports. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company had revenue of $435.35 million for the quarter, compared to analysts’ expectations of $414.58 million. During the same quarter in the previous year, the firm posted ($0.01) EPS. LifeStance Health Group’s revenue was up 26.1% on a year-over-year basis.

Here are the key takeaways from LifeStance Health Group’s conference call:

Positive Sentiment: LifeStance reported strong second-quarter performance, with revenue up 26% to $435 million, visits rising 19% to 2.6 million, and Adjusted EBITDA nearly doubling to $66 million. Adjusted EBITDA margin reached 15.2%, up more than 500 basis points year over year.
Positive Sentiment: Management raised full-year 2026 guidance, now projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million. The midpoint implies 20% revenue growth and a 13.2% Adjusted EBITDA margin.
Positive Sentiment: Clinician additions and productivity remain key growth drivers, with 193 net clinicians added in the quarter to reach 8,542, while visits per average clinician increased 7% for the third consecutive quarter. Management said only about 70% of clinician-provided capacity is currently being utilized, indicating further runway.
Positive Sentiment: Specialty services, including TMS and SPRAVATO, are expanding and generated roughly $50 million of revenue last year, with expected growth of about 40% in 2026. The company also sees significant opportunity from geographic expansion, tuck-in acquisitions, AI-enabled tools, and a planned 2027 EHR rollout.
Negative Sentiment: Third-quarter Adjusted EBITDA guidance of $49 million-$59 million implies a sequential decline as LifeStance increases spending on technology, patient acquisition, clinical excellence, compensation, and support staff. Management also cautioned that the phased EHR implementation could cause a temporary productivity dip.

LifeStance Health Group Price Performance

NASDAQ:LFST traded up $0.18 during trading hours on Friday, hitting $10.84. 3,793,084 shares of the company’s stock traded hands, compared to its average volume of 3,253,660. LifeStance Health Group has a 52 week low of $3.90 and a 52 week high of $11.76. The business’s fifty day simple moving average is $9.95 and its two-hundred day simple moving average is $8.05. The company has a quick ratio of 1.48, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.20 billion, a P/E ratio of 83.39 and a beta of 1.14.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

Insiders Place Their Bets

In other LifeStance Health Group news, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This trade represents a 62.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Eric Shuey sold 243,362 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director owned 867,562 shares in the company, valued at approximately $6,957,847.24. This trade represents a 21.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,612,394 shares of company stock worth $62,938,451 in the last ninety days. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in shares of LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after purchasing an additional 1,966 shares during the last quarter. Vident Advisory LLC boosted its stake in LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after buying an additional 2,447 shares during the last quarter. Xponance LLC increased its stake in shares of LifeStance Health Group by 26.4% in the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after acquiring an additional 2,745 shares during the last quarter. Legal & General Group Plc increased its stake in shares of LifeStance Health Group by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock worth $746,000 after acquiring an additional 3,331 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its holdings in shares of LifeStance Health Group by 19.3% during the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock worth $120,000 after acquiring an additional 3,525 shares during the period. Institutional investors own 85.50% of the company’s stock.

Wall Street Analyst Weigh In

LFST has been the subject of a number of recent research reports. The Goldman Sachs Group assumed coverage on LifeStance Health Group in a research report on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Barclays boosted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.62.

View Our Latest Analysis on LifeStance Health Group

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.